These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 31751428)
21. Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China. Wang Z; Zhang M; Zhang R; Liu L; Shen Y; Wang J; Lu H BMC Infect Dis; 2019 Apr; 19(1):313. PubMed ID: 30961560 [TBL] [Abstract][Full Text] [Related]
22. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya. Onywera H; Maman D; Inzaule S; Auma E; Were K; Fredrick H; Owiti P; Opollo V; Etard JF; Mukui I; Kim AA; Zeh C PLoS One; 2017; 12(2):e0171124. PubMed ID: 28178281 [TBL] [Abstract][Full Text] [Related]
23. Limited evolution but increasing trends of primary non-nucleoside reverse transcriptase inhibitor resistance mutations in therapy-naive HIV-1-infected individuals in India. Neogi U; Gupta S; Palchaudhuri R; Rao SD; Shastri S; Diwan V; Laishram RS; De Costa A; Shet A Antivir Ther; 2014; 19(8):813-8. PubMed ID: 24699043 [TBL] [Abstract][Full Text] [Related]
24. Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali. Sylla M; Dolo O; Maiga AI; Traore FT; Coulibaly YA; Togo J; Fofana DB; Dicko-Traore F; Doumbia S; Orsega S; Diallo S; Murphy RL; Calvez V; Marcelin AG Arch Pediatr; 2019 Jul; 26(5):254-258. PubMed ID: 31307909 [TBL] [Abstract][Full Text] [Related]
25. [Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases]. Yalçınkaya T; Köse S Mikrobiyol Bul; 2014 Oct; 48(4):585-95. PubMed ID: 25492654 [TBL] [Abstract][Full Text] [Related]
26. Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia. Seu L; Mulenga LB; Siwingwa M; Sikazwe I; Lambwe N; Guffey MB; Chi BH J Med Virol; 2015 Jul; 87(7):1149-57. PubMed ID: 25754408 [TBL] [Abstract][Full Text] [Related]
27. HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naïve to HAART in Cameroon. Burda ST; Viswanath R; Zhao J; Kinge T; Anyangwe C; Tinyami ET; Haldar B; Powell RL; Jarido V; Hewlett IK; Nyambi PN J Med Virol; 2010 Feb; 82(2):187-96. PubMed ID: 20029816 [TBL] [Abstract][Full Text] [Related]
28. Archiving of mutations in HIV-1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTP-READY study. Fokam J; Mpouel Bala ML; Santoro MM; Takou D; Tala V; Beloumou G; Ngoufack ES; Chenwi C; Pabo Willy Leroi T; Njume D; Teto G; Dambaya B; Djupsa S; Sosso S; Ateba F; Kamta C; Bala L; Njom Nlend AE; Koki Ndombo P; Colizzi V; Perno CF; Ndjolo A HIV Med; 2022 Jul; 23(6):629-638. PubMed ID: 34951111 [TBL] [Abstract][Full Text] [Related]
29. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Hamers RL; Wallis CL; Kityo C; Siwale M; Mandaliya K; Conradie F; Botes ME; Wellington M; Osibogun A; Sigaloff KC; Nankya I; Schuurman R; Wit FW; Stevens WS; van Vugt M; de Wit TF; Lancet Infect Dis; 2011 Oct; 11(10):750-9. PubMed ID: 21802367 [TBL] [Abstract][Full Text] [Related]
30. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. Johnston V; Cohen K; Wiesner L; Morris L; Ledwaba J; Fielding KL; Charalambous S; Churchyard G; Phillips A; Grant AD J Infect Dis; 2014 Mar; 209(5):711-20. PubMed ID: 23943851 [TBL] [Abstract][Full Text] [Related]
31. Protease and gag diversity and drug resistance mutations among treatment-naive Mexican people living with HIV. Climaco-Arvizu S; Flores-López V; González-Torres C; Gaytán-Cervantes FJ; Hernández-García MC; Zárate-Segura PB; Chávez-Torres M; Tesoro-Cruz E; Pinto-Cardoso SM; Bekker-Méndez VC BMC Infect Dis; 2022 May; 22(1):447. PubMed ID: 35538426 [TBL] [Abstract][Full Text] [Related]
32. Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon. Teto G; Tagny CT; Mbanya D; Fonsah JY; Fokam J; Nchindap E; Kenmogne L; Njamnshi AK; Kanmogne GD Sci Rep; 2017 Oct; 7(1):14136. PubMed ID: 29074854 [TBL] [Abstract][Full Text] [Related]
33. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. Hosseinipour MC; van Oosterhout JJ; Weigel R; Phiri S; Kamwendo D; Parkin N; Fiscus SA; Nelson JA; Eron JJ; Kumwenda J AIDS; 2009 Jun; 23(9):1127-34. PubMed ID: 19417582 [TBL] [Abstract][Full Text] [Related]
34. Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1 infected individuals in Ethiopia. Kiros M; Alemayehu DH; Geberekidan E; Mihret A; Maier M; Abegaz WE; Mulu A Retrovirology; 2020 Sep; 17(1):33. PubMed ID: 32993693 [TBL] [Abstract][Full Text] [Related]
35. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463 [TBL] [Abstract][Full Text] [Related]
36. Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study. Adawaye C; Fokam J; Kamangu E; Alio HM; Chahad AM; Susin F; Moussa AM; Bertin TH; Tidjani A; Vaira D; Moutschen M BMC Res Notes; 2017 Nov; 10(1):589. PubMed ID: 29126456 [TBL] [Abstract][Full Text] [Related]
37. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Vray M; Meynard JL; Dalban C; Morand-Joubert L; Clavel F; Brun-Vézinet F; Peytavin G; Costagliola D; Girard PM; Antivir Ther; 2003 Oct; 8(5):427-34. PubMed ID: 14640390 [TBL] [Abstract][Full Text] [Related]
38. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey. Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G; Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867 [TBL] [Abstract][Full Text] [Related]
39. HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique. Ismael N; Gemusse H; Mahumane I; Laurindo O; Magul C; Baxter C; Wilkinson E; Hofstra LM; Wagar N; Bila D; Mabunda N; da Silva J; Oliveira T; Raizes E; Preiser W; Manuel P; Ramos A; Vúbil A BMC Infect Dis; 2024 Jul; 24(1):748. PubMed ID: 39075381 [TBL] [Abstract][Full Text] [Related]
40. HIV-1 drug resistance and genetic diversity in people with HIV-1 in Cape Verde. Gonçalves P; Barreto J; Santos M; Leal S; Marcelino J; Abecasis A; Palladino C; Taveira N AIDS; 2024 Jul; 38(8):1101-1110. PubMed ID: 38349224 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]